Cargando…
TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis
Cytoplasmic TDP-43 aggregates are a hallmark of amyotrophic lateral sclerosis (ALS). Today, only two drugs are available for ALS treatment, and their modest effect prompts researchers to search for new therapeutic options. TDP-43 represents one of the most promising targets for therapeutic intervent...
Autores principales: | Lanznaster, Débora, Bourgeais, Jérôme, Bruno, Clement, Hergesheimer, Rudolf C., Thepault, Rose-Anne, Vourc’h, Patrick, Corcia, Philippe, Andres, Christian R., Herault, Olivier, Blasco, Hélène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016571/ https://www.ncbi.nlm.nih.gov/pubmed/31888078 http://dx.doi.org/10.3390/cells9010068 |
Ejemplares similares
-
Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells
por: Hergesheimer, Rudolf, et al.
Publicado: (2020) -
The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
por: Hergesheimer, Rudolf C, et al.
Publicado: (2019) -
Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2020) -
Metabolomics: A Tool to Understand the Impact of Genetic Mutations in Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2020) -
Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2022)